Luca Valerio

Dr. Luca Valerio

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SBStefano Barco
Stefano Barco
SMSeyed Hamidreza Mahmoudpour
Seyed Hamidreza Mahmoudpour
LVLuca Valerio
Luca Valerio
FKFrederikus A Klok
Frederikus A Klok
TMThomas Münzel
Thomas Münzel
SKStavros Konstantinides
Stavros Konstantinides

1 January 2021 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SBStefano Barco
Stefano Barco
LVLuca Valerio
Luca Valerio
WAWalter Ageno
Walter Ageno
ACAlexander T Cohen
Alexander T Cohen
SGSamuel Z Goldhaber
Samuel Z Goldhaber
SKStavros V Konstantinides
Stavros V Konstantinides

29 April 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LVLuca Valerio
Luca Valerio
AMAnna C Mavromanoli
Anna C Mavromanoli
SBStefano Barco
Stefano Barco
CAChristina Abele
Christina Abele
DBDorothea Becker
Dorothea Becker
SRStephan Rosenkranz
Stephan Rosenkranz
Aims: To systematically assess late outcomes of acute pulmonary embolism (PE) and to investigate the clinical implications of post-PE impairment (PPEI) fulfilling prospectively defined criteria. Methods and results: A prospective multicentre observational cohort study was conducted in 17 large-volume centres across Germany. Adult consecutive patients with confirmed acute symptomatic PE were followed with a standardized assessment plan and pre-defined visits at 3, 12, and 24 months. The co-primary outcomes were (i) diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH), and (ii) PPEI, a combination of persistent or worsening clinical, functional, biochemical, and imaging parameters during follow-up. A total of 1017 patients (45% women, median age 64 years) were included in the primary analysis. They were followed for a median duration of 732 days after PE diagnosis. The CTEPH was diagnosed in 16 (1.6%) patients, after a median of 129 days; the estimated 2-year cumulative incidence was 2.3% (1.2–4.4%). Overall, 880 patients were evaluable for PPEI; the 2-year cumulative incidence was 16.0% (95% confidence interval 12.8–20.8%). The PPEI helped to identify 15 of the 16 patients diagnosed with CTEPH during follow-up (hazard ratio for CTEPH vs. no CTEPH 393; 95% confidence interval 73–2119). Patients with PPEI had a higher risk of re-hospitalization and death as well as worse quality of life compared with those without PPEI. Conclusion: In this prospective study, the cumulative 2-year incidence of CTEPH was 2.3%, but PPEI diagnosed by standardized criteria was frequent. Our findings support systematic follow-up of patients after acute PE and may help to optimize guideline recommendations and algorithms for post-PE care.

1 June 2012 in Health Policy
Verified
Journal Article
Closed access
ABAntonio Giulio de Belvis
Antonio Giulio de Belvis
FFFrancesca Ferré
Francesca Ferré
MSMaria Lucia Specchia
Maria Lucia Specchia
LVLuca Valerio
Luca Valerio
GFGiovanni Fattore
Giovanni Fattore
WRWalter Ricciardi
Walter Ricciardi

1 December 2020 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
LRLoris Roncon
Loris Roncon
MZMarco Zuin
Marco Zuin
SBStefano Barco
Stefano Barco
LVLuca Valerio
Luca Valerio
GZGiovanni Zuliani
Giovanni Zuliani
SKStavros Konstantinides
Stavros Konstantinides

22 May 2020 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
LVLuca Valerio
Luca Valerio
FZFederica Zane
Federica Zane
CSClara Sacco
Clara Sacco
SGSerena Granziera
Serena Granziera
TNTommaso Nicoletti
Tommaso Nicoletti
SBStefano Barco
Stefano Barco
Background: Lemierre syndrome is characterized by head/neck vein thrombosis and septic embolism usually complicating an acute oropharyngeal bacterial infection in adolescents and young adults. We described the course of Lemierre syndrome in the contemporary era.Methods: In our individual‐level analysis of 712 patients (2000–2017), we included cases described as Lemierre syndrome if these criteria were met: (i) primary site of bacterial infection in the head/neck; (ii) objectively confirmed local thrombotic complications or septic embolism. The study outcomes were new or recurrent venous thromboembolism or peripheral septic lesions, major bleeding, all‐cause death and clinical sequelae.Results: The median age was 21 (Q1–Q3: 17–33) years, and 295 (41%) were female. At diagnosis, acute thrombosis of head/neck veins was detected in 597 (84%) patients, septic embolism in 582 (82%) and both in 468 (80%). After diagnosis and during in‐hospital follow‐up, new venous thromboembolism occurred in 34 (5.2%, 95% CI 3.8–7.2%) patients, new peripheral septic lesions became evident in 76 (11.7%; 9.4–14.3%). The rate of either was lower in patients who received anticoagulation (OR: 0.59; 0.36–0.94), higher in those with initial intracranial involvement (OR: 2.35; 1.45–3.80). Major bleeding occurred in 19 patients (2.9%; 1.9–4.5%), and 26 died (4.0%; 2.7–5.8%). Clinical sequelae were reported in 65 (10.4%, 8.2–13.0%) individuals, often consisting of cranial nerve palsy (n = 24) and orthopaedic limitations (n = 19).Conclusions: Patients with Lemierre syndrome were characterized by a substantial risk of new thromboembolic complications and death. This risk was higher in the presence of initial intracranial involvement. One‐tenth of survivors suffered major clinical sequelae.